-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Liver cancer is a common malignant tumor in my country.
Liver cancer is a common malignant tumor in my country.
Recently, the team of Professor Qu Zengqiang from Shanghai Oriental Hepatobiliary Surgery Hospital published a data in Hepatology International.
Research data showed that in terms of overall survival, the 1-year and 2-year OS rates of the lenvatinib+TACE group were 88.
Research data showed that in terms of overall survival, the 1-year and 2-year OS rates of the lenvatinib+TACE group were 88.
The ORR of the lenvatinib+TACE group was 68.
The ORR of the lenvatinib+TACE group was 68.
From the perspective of safety, the most common adverse events in the combination therapy group were albumin reduction (55.
From the perspective of safety, the most common adverse events in the combination therapy group were albumin reduction (55.
In summary, lenvatinib+TACE significantly improved the clinical prognosis of unresectable liver cancer compared with TACE alone.
In summary, lenvatinib+TACE significantly improved the clinical prognosis of unresectable liver cancer compared with TACE alone.
Original source:
Zhigang Fu, Xiaowei Li, Jiaming Zhong, et al.
Zhigang Fu, Xiaowei Li, Jiaming Zhong, et al.
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Hepatol Int.
2021 Apr 20.
doi: 10.
1007/s12072-021-10184- 9.
Online ahead of print.
Leave a message here
